Stay updated on Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial
Sign up to get notified when there's something new on the Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial page.

Latest updates to the Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial page
- CheckyesterdayChange DetectedAdded a dedicated Locations section with state-level site listings (California, Connecticut, District of Columbia, Maryland, Massachusetts, Minnesota, Ohio, Texas, Washington). The page revision was updated from v3.3.2 to v3.3.3.SummaryDifference1%

- Check9 days agoChange DetectedThe old and new page screenshots show no noticeable changes to the page content or layout.SummaryDifference0.2%

- Check16 days agoChange DetectedThe new page shows only layout and styling updates; there are no edits to core study details, eligibility criteria, interventions, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check23 days agoChange DetectedThe only visible change is a revision label update from v3.2.0 to v3.3.2, with no changes to study content, criteria, or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check30 days agoChange DetectedGovernment funding status notice and NIH Clinical Center operating status banner were removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check37 days agoChange DetectedThe new screenshot appears to reflect cosmetic UI/formatting adjustments with no changes to core study content, endpoints, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vatiquinone for Mitochondrial Disease and Refractory Epilepsy Clinical Trial page.